Brineura (cerliponase alfa)

Indications for Prior Authorization

Brineura (cerliponase alfa)
  • For diagnosis of Neuronal Ceroid Lipofuscinosis Type 2
    Indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.

Criteria

Brineura

Prior Authorization (Initial Authorization)

Length of Approval: 12 Month(s)

  • Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2) (also known as tripeptidyl peptidase 1 (TPP1) deficiency)
  • AND
  • Diagnosis is confirmed by tripeptidyl peptidase 1 (TPP1) enzyme detected by a dried blood spot test and CLN2 genotype analysis
  • AND
  • Patient does not have acute intraventricular access-related complications (e.g., leakage, device failure, or device-related infections)
  • AND
  • Patient does not have ventriculoperitoneal shunts
  • AND
  • Prescribed by or in consultation with a neurologist with expertise in the diagnosis of CLN2
  • AND
  • Administered in a healthcare setting by, or under the direction of, a physician knowledgeable in intraventricular administration and hypersensitivity reactions including anaphylaxis [A]
Brineura

Prior Authorization (Reauthorization)

Length of Approval: 12 Month(s)

  • Patient does not have acute intraventricular access-related complications (e.g., leakage, device failure, or device-related infections)
  • AND
  • Patient does not have ventriculoperitoneal shunts
  • AND
  • Administered in a healthcare setting by, or under the direction of, a physician knowledgeable in intraventricular administration and hypersensitivity reactions including anaphylaxis [A]
  • AND
  • Patient demonstrates positive clinical response to therapy (e.g., improvement in walking or crawling, or no evidence of disease progression)
P & T Revisions

2024-09-04, 2024-05-01, 2023-06-26, 2023-06-19, 2022-04-25, 2021-04-22, 2020-04-09

  1. Batten Disease Support and Research Association: Batten Disease Neuronal Ceroid Lipofuscinosis. Available at: http://bdsra.org/wp-content/uploads/2012/01/Batten-Disease-An-Easy-To-Understand-Guide.pdf. Accessed March 29, 2022.
  2. Brineura Prescribing Information. BioMarin Pharmaceutical Inc. Novato, CA. July 2024.
  3. Fietz M, AlSayed M, Burke D, et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. Molecular Genetics and Metabolism. 2016 Sep;119(1-2):160-7.
  4. National Institutes of Health (NIH). Bethesda, MD. CLN2 Disease. Available at: https://ghr.nlm.nih.gov/condition/cln2-disease. Accessed March 29, 2022.

  1. Brineura (cerliponase alfa) is for intraventricular use only and should be administered by, or under the direction of a physician knowledgeable in intraventricular administration. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Administration of Brineura should be supervised by a healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis. Initiate Brineura in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. [2]

  • 2024-09-04: Criteria updated due to expanded indication.
  • 2024-05-01: 2024 Annual Review. No criteria updates.
  • 2023-06-26: Update effective date
  • 2023-06-19: Annual Review
  • 2022-04-25: Annual Review
  • 2021-04-22: Annual Review
  • 2020-04-09: Annual Review

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone